A breast cancer vaccine by Generex Biotechnology Corporation has deemed successful thus far. The corporation announced today that Phase 2 of the clinical data, which is from a study
that diminishes the chances of cancer recurrence, is complete, and Phase 3 will begin shortly.
"Women with breast cancers expressing low levels of HER2 do not benefit from targeted HER2 therapies that are currently available," said Dr. George E. Peoples, a leading researcher in adjuvant breast cancer vaccine development. "Our research is focused on reducing the recurrence of cancer using a woman's own immune system to fight her disease, including breast cancers that express low levels of HER2. The AE37 vaccine is based on over 5 years of research and continues to show promise in a well-designed and ongoing randomized Phase 2 clinical trial that if positive, will allow rapid transition to Phase 3."
According to the Susan G. Komen Foundation, it is recommended that women start scheduling annual mammograms once they turn 40. If a woman has an extensive family history of the disease, she may want to make these appointments earlier, as this is a known risk factor for breast cancer.